| 前收市價 | 4.1200 |
| 開市 | 4.0700 |
| 買盤 | 4.0500 x 2300 |
| 賣出價 | 4.0800 x 100 |
| 今日波幅 | 4.0100 - 4.1050 |
| 52 週波幅 | 3.5300 - 11.3600 |
| 成交量 | |
| 平均成交量 | 7,566,738 |
| 市值 | 569.749M |
| Beta 值 (5 年，每月) | 1.60 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.4100 |
| 業績公佈日 | 2024年5月07日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 15.40 |
- Reuters
UPDATE 4-Novavax investor Shah Capital pushes for board shakeup
Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to help tackle "underperformance" at the company and improve its share price. The hedge fund nominated Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of Quantiva Health, to Novavax's eight-member board, saying the duo had the experience in setting the company's strategic direction.
Motley FoolBetter Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs?
Motley FoolDown 60% From Its 52-Week High, Is Novavax Stock a Buy?
Is there still too much risk surrounding this business?
